Stable antibody formulation
The present invention provides a pharmaceutical formulation comprising an antibody or antigen-binding fragment thereof that exhibits high stability; along with methods of use thereof.
1 . A pharmaceutical formulation comprising an isolated antibody or antigen-binding fragment thereof that binds specifically to IGF1R, a buffer and sucrose.
2 . The formulation of claim 1 wherein the buffer is phosphate buffer, citrate buffer, histidine buffer, glycine buffer or acetate buffer.
3 . The pharmaceutical formulation of claim 1 comprising an antibody or antigen-binding fragment thereof that binds specifically to IGF1R, a buffer and sucrose at a pH of about 5.5 to about 6.0.
4 . The formulation of claim 1 wherein the buffer is phosphate buffer, citrate buffer, histidine buffer, glycine buffer or acetate buffer.
5 . The formulation of claim 1 wherein the antibody or fragment comprises one or more light chain complementarity determining regions selected from the group consisting of SEQ ID NOs: 1-3; and/or one or more heavy chain complementarity determining regions selected from the group consisting of SEQ ID NOs: 4-7.
6 . The pharmaceutical formulation of claim 1 comprising an antibody or antigen-binding fragment thereof comprising a light chain variable region selected from the group consisting of amino acids 20-128 of SEQ ID NOs: 8-14 and/or a heavy chain variable region selected from the group consisting of amino acids 20-137 of SEQ ID NOs: 15-17; a buffer and sucrose at a pH of about 5.5 to about 6.0.
7 . The formulation of claim 1 which is lyophilized.
8 . The formulation of claim 1 which is sterile.
9 . The formulation of claim 1 wherein the antibody or fragment comprises a heavy chain constant region selected from the group consisting of γ1, γ2, γ3 and γ4 or a κ light chain constant region.
10 . The formulation of claim 1 in an aqueous solution.
11 . The formulation of claim 1 wherein the antibody or fragment concentration is about 20 mg/ml.
12 . The formulation of claim 1 wherein the concentration of buffer is about 1 to about 20 mM.
13 . The formulation of claim 1 wherein the concentration of sucrose is about 5 to about 70 mg/ml.
14 . The formulation of claim 1 in association with a further therapeutic agent.
15 . The formulation of claim 1 wherein the further therapeutic agent is one or more members selected from the group consisting of:
16 . The formulation of claim 1 comprising, in a single composition, the antibody or fragment comprising a light chain variable region selected from the group consisting of amino acids 20-128 of SEQ ID NOs: 8-14 and/or a heavy chain variable region selected from the group consisting of amino acids 20-137 of SEQ ID NOs: 15-17; acetate; acetic acid and sucrose at a pH of about 5.5 in association with a further therapeutic agent.
17 . The pharmaceutical formulation of claim 1 , at a pH of 5.5, comprising:
(a) 20 mg/ml of an antibody or antigen-binding fragment thereof comprising a light chain variable region selected from the group consisting of amino acids 20-128 of SEQ ID NOs: 8-14 and/or a heavy chain variable region selected from the group consisting of amino acids 20-137 of SEQ ID NOs: 15-17;
(b) 2.3 mg/ml of sodium acetate trihydrate;
(c) 0.18 mg/ml of glacial acetic acid;
(d) 70 mg/ml of Sucrose; and
(e) water.
18 . A lyophilized pharmaceutical formulation, at a pH of 5.5, which, when reconstituted comprises:
(a) 20 mg/ml of a therapeutically effective amount of an antibody or antigen-binding fragment thereof comprising a light chain variable region selected from the group consisting of amino acids 20-128 and/or a heavy chain variable region selected from the group consisting of amino acids 20-137 of SEQ ID NOs: 15-17;
(b) 2.3 mg/ml of sodium acetate trihydrate;
(c) 0.18 mg/ml of glacial acetic acid; and
(d) 70 mg/ml of Sucrose; and
(e) water.
19 . A vessel comprising the formulation of claim 1 .
20 . The vessel of claim 19 which is a glass vial.
21 . An injection device comprising the formulation of claim 1 .
22 . The injection device of claim 21 which is a hypodermic needle and syringe.
23 . A kit comprising
(a) the formulation of claim 1 in a vessel or injection device; and
(b) a package insert comprising one or more items of information regarding said formulation selected from the group consisting of pharmacokinetics, pharmacodynamics, clinical studies, efficacy parameters, indications and usage, contraindications, warnings, precautions, adverse reactions, overdosage, proper dosage and administration, how supplied, proper storage conditions, references and patent information.
24 . A method for treating or preventing a medical disorder mediated by IGF1R, IGF-1 and/or IGF-2, in a subject, comprising administering, to the subject, a therapeutically effective amount of a formulation of claim 1 .
25 . The method of claim 24 wherein the medical disorder is selected from the group consisting of neuroblastoma, rhabdomyosarcoma, osteosarcoma, pediatric cancer, acromegaly, ovarian cancer, pancreatic cancer, benign prostatic hyperplasia, breast cancer, prostate cancer, bone cancer, lung cancer, colorectal cancer, cervical cancer, synovial sarcoma, bladder cancer, gastric cancer, Wilm's cancer, ovarian cancer, benign prostatic hyperplasia (BPH), diarrhea associated with metastatic carcinoid and vasoactive intestinal peptide secreting tumors , VIPoma, Werner-Morrison syndrome, kidney cancer, renal cell carcinoma, transitional cell cancer, Ewing Sarcoma, leukemia, acute lymphoblastic leukemia, brain cancer, glioblastoma, non-glioblastoma brain cancer, meningioma, pituitary adenoma, vestibular schwannoma, a primitive neuroectodermal tumor, medulloblastoma, astrocytoma, oligodendroglioma, ependymoma, choroid plexus papilloma, gigantism, psoriasis, atherosclerosis, smooth muscle restenosis of blood vessels, inappropriate microvascular proliferation, acromegaly, gigantism, psoriasis, atherosclerosis, smooth muscle restenosis of blood vessels or inappropriate microvascular proliferation, Grave's disease, multiple sclerosis, systemic lupus erythematosus, Hashimoto's Thyroiditis, Myasthenia Gravis, auto-immune thyroiditis and Bechet's disease.
26 . The method of claim 24 wherein the subject is administered a further therapeutic agent in association with the formulation.
27 . The method of claim 26 wherein the further therapeutic agent is selected from the group consisting of:
28 . The method of claim 24 wherein the subject is a human.
29 . The method of claim 24 wherein the formulation is administered to the subject parenterally.
30 . The method of claim 24 wherein the formulation is at about pH 5.5 and comprises:
(a) 20 mg/ml of a therapeutically effective amount of an antibody or antigen-binding fragment thereof comprising a light chain variable region selected from the group consisting of amino acids 20-128 of SEQ ID NOs: 8-14 and/or a heavy chain variable region selected from the group consisting of amino acids 20-137 of SEQ ID NOs: 15-17;
(b) 2.3 mg/ml of sodium acetate trihydrate;
(c) 0.18 mg/ml of glacial acetic acid;
(d) 70 mg/ml of Sucrose; and
(e) water.
31 . A method for stabilizing an antibody or antigen-binding fragment thereof comprising a light chain variable region selected from the group consisting of amino acids 20-128 of SEQ ID NOs: 20-128 and/or a heavy chain variable region selected from the group consisting of amino acids 20-137 of SEQ ID NOs: 15-17; comprising combining said antibody or fragment with acetate; acetic acid and sucrose, optionally, at a pH of about 5.5.
32 . The method of claim 31 wherein the antibody or fragment concentration is about 20 mg/ml.
33 . The method of claim 31 wherein the concentration of acetate is about 2.3 mg/ml, the concentration of acetic acid is about 0.18 mg/ml and the concentration of sucrose is about 70 mg/ml.